Nanalysis Completes Final Tranche of $3.4 Million Private Placement Successfully

Nanalysis Completes Final Tranche of $3.4 Million Offering

Nanalysis Scientific Corp. has made significant strides in its financial initiatives by successfully closing the second tranche of its private placement, raising a total of $3.4 million. This offering comes after a series of strategic announcements made in December 2025. In this final stage, the company issued a remarkable 6,145,300 units at $0.15 per unit, amounting to additional gross proceeds of $921,795. The total units allocated through this offering now stand at 22,671,583.

Each unit issued consists of a common share along with half of a common share purchase warrant. Notably, the warrant grants the holder the right to acquire another share at an exercise price of $0.20, valid until 4 p.m. Calgary time, two years from the closing date. A unique aspect of this offering is the acceleration provision of the warrants. If the closing price of the Nanalysis shares on the TSX Venture Exchange reaches or surpasses $0.30 for ten consecutive trading days, the company may choose to accelerate the expiry date to thirty days from notice.

The completion of this second tranche also involved a nominal cash commission fee of $2,000 paid to Leede Financial Inc. As with all securities under this offering, a statutory hold period of four months and one day applies, complying with relevant securities regulations.

Nanalysis Scientific Corp. specializes in the development and manufacturing of portable Nuclear Magnetic Resonance (NMR) spectrometers, instruments critically utilized across various industries including pharmaceuticals, biotech, food, and materials. Their services division is expanding rapidly and includes a significant long-term contract worth $160 million with the Canadian Air Transport Security Authority (CATSA) for maintaining security scanners at over 80 Canadian airports.

Despite these advancements, the company emphasizes caution surrounding forward-looking statements made in their announcements. Such statements involve assumptions that may not hold true, indicating that actual results could vary significantly due to various risks and uncertainties.

Overall, the successful closure of this financial offering not only strengthens Nanalysis’s fiscal health but also positions them favorably for future growth in a competitive landscape. Investors and stakeholders are optimistic about what this means for the company's trajectory moving forward, especially given their strong presence in the NMR industry, alongside emerging opportunities within their service-focused divisions.

As Nanalysis moves ahead, they remain dedicated to transparency and compliance, ensuring that their operations align with securities regulations while fostering growth and innovation in instrumentation technologies. This strategic financial maneuver is anticipated to enhance their commitment to developing cutting-edge NMR technologies that are vital for a myriad of scientific and industrial applications.